Alexander Zweibach
Hematology & Oncology · New Braunfels, TXNPI 1659343358
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,697 of the $5,213 with a category attached, or 70.9%. It is spread thinly across 39 manufacturers, the largest accounting for just 22.4%. Reporting peaked in 2019 at $3,257 and has fallen 96.9% since, to $100 in 2023.
Across 273 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- E.r. Squibb & Sons, L.L.C.$393
- Genentech USA, Inc.$381
- Novartis$377
- Johnson & Johnson$371
- Seagen Inc.$194
- plus $2K from 33 others
Across 148 payments — averaging $828.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$116K
- Acerta Pharma LLC$6K
What the payments were for
- Consulting fees$1,13022%
- Food & beverage$3,69771%
- Education$3867%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 4 | $1,170 |
| E.r. Squibb & Sons, L.L.C. | 37 | $393 |
| Genentech USA, Inc. | 31 | $381 |
| Novartis | 22 | $377 |
| Johnson & Johnson(2 entities) | 21 | $371 |
| Seagen Inc. | 8 | $194 |
| Incyte Corporation | 10 | $190 |
| Merck | 14 | $178 |
| Pfizer | 17 | $172 |
| Sanofi | 10 | $160 |
| Amgen | 8 | $151 |
| AstraZeneca(2 entities) | 10 | $140 |
| Eisai Inc. | 8 | $136 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $118 |
| Lilly USA, LLC | 14 | $115 |
| Bristol Myers Squibb | 6 | $104 |
| Astellas Pharma US Inc | 5 | $76 |
| Bayer | 4 | $75 |
| Verastem, Inc. | 4 | $73 |
| Tersera Therapeutics LLC | 3 | $63 |
| Dendreon Pharmaceuticals LLC | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Puma Biotechnology, Inc. | 3 | $48 |
| Dova Pharmaceuticals | 2 | $46 |
| AbbVie | 2 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Karyopharm Therapeutics Inc. | 2 | $32 |
| EMD Serono, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Array Biopharma Inc | 2 | $28 |
| Rigel Pharmaceuticals, Inc. | 2 | $24 |
| Exelixis Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Sandoz | 1 | $13 |
| Taiho Oncology, Inc. | 1 | $11 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,213 in reported general payments places this provider in the 55th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in New Braunfels
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.